If you take levothyroxine for hypothyroidism and still feel terrible, or if your thyroid antibodies keep climbing despite medication, your gut may be part of the problem. The thyroid gland and the gastrointestinal tract are connected through multiple biological pathways that researchers are calling the thyroid-gut axis. Your gut bacteria help absorb the nutrients needed to make thyroid hormones. They participate in converting inactive T4 into active T3. They modulate the immune responses that drive Hashimoto's thyroiditis, the leading cause of hypothyroidism in developed countries. And in the other direction, thyroid hormones influence gut motility and microbial composition, meaning that thyroid dysfunction can worsen gut health, which can further impair thyroid function, creating a cycle that is difficult to break from either end alone. This is not a speculative connection. Hashimoto's patients have measurably different gut microbiomes. Hypothyroid patients have elevated rates of SIBO. And an ongoing clinical trial called IMITHOT is testing whether fecal microbiota transplantation can actually change the course of thyroid autoimmunity. Here is where the science currently stands.
How gut bacteria participate in thyroid hormone metabolism
Thyroid hormone metabolism involves several steps where gut bacteria play a documented role. The thyroid gland primarily produces thyroxine (T4), which is relatively inactive. T4 must be converted to triiodothyronine (T3) to exert its metabolic effects. Most of this conversion happens in the liver and kidneys, but approximately 20% occurs in the gut, where bacterial enzymes contribute to the deiodination and sulfation reactions that activate or inactivate thyroid hormones (Peeters and Visser, 2017).
Specifically, gut bacteria produce enzymes called iodothyronine deiodinases that catalyze the removal of iodine atoms from T4 to produce T3. They also produce sulfatase enzymes that can reactivate sulfated thyroid hormone metabolites, effectively recycling thyroid hormones that would otherwise be excreted. The net effect is that a healthy, diverse gut microbiome contributes to the pool of active T3 available to the body. When gut dysbiosis reduces the populations of bacteria producing these enzymes, peripheral T3 availability may decrease even when thyroid gland output and liver conversion are normal.
Beyond hormone conversion, the gut microbiome affects the absorption of two minerals essential for thyroid hormone synthesis: iodine and selenium. Iodine is a structural component of T3 and T4, and selenium is required for the deiodinase enzymes that convert between them. Gut inflammation and dysbiosis can impair the intestinal absorption of both nutrients, creating functional deficiencies that limit thyroid hormone production even when dietary intake appears adequate (Knezevic et al., 2020). This may partly explain why some hypothyroid patients do not improve with standard supplementation.
The Hashimoto's microbiome: what studies consistently find
Hashimoto's thyroiditis is an autoimmune condition in which the immune system attacks thyroid tissue, gradually destroying the gland's ability to produce hormones. It is the most common cause of hypothyroidism in iodine-sufficient populations and affects roughly 5% of the general population, with a strong female predominance. Multiple studies have now characterized the gut microbiome of Hashimoto's patients, and the findings are remarkably consistent.
Zhao et al. (2018) conducted one of the most cited studies, comparing the gut microbiomes of 28 Hashimoto's patients to 16 healthy controls matched for age, sex, and diet. The Hashimoto's group showed significantly reduced microbial diversity and specific alterations including decreased Bifidobacterium and Lactobacillus populations and increased Bacteroides fragilis. A larger 2020 study by Ishaq et al. with 45 Hashimoto's patients confirmed the diversity reduction and found additional alterations in Firmicutes to Bacteroidetes ratios. Both studies found that the degree of dysbiosis correlated with thyroid antibody levels, suggesting a dose-response relationship between gut microbial disruption and autoimmune intensity.
âšī¸The correlation between gut dysbiosis severity and thyroid antibody levels is interesting but does not establish causation. It is possible that more severe autoimmune disease causes more gut dysfunction (through impaired motility, medication effects, or immune-mediated intestinal changes) rather than the gut driving the autoimmunity. The IMITHOT trial is designed to help answer this chicken-and-egg question.
The bidirectional loop: how thyroid dysfunction changes the gut
The thyroid-gut axis is genuinely bidirectional, and the gut-to-thyroid direction gets most of the attention in microbiome discussions while the thyroid-to-gut direction is equally important clinically. Thyroid hormones directly regulate gut motility. T3 and T4 influence the contractile function of intestinal smooth muscle, and hypothyroidism slows gut transit time significantly. This reduced motility creates a more favorable environment for bacterial overgrowth in the small intestine.
Patil (2014) reviewed the literature on gastrointestinal manifestations of thyroid disease and noted that hypothyroid patients have elevated rates of constipation, gastroparesis, and SIBO. The constipation associated with hypothyroidism is often attributed simply to slowed motility, but the downstream effects on the microbiome are underappreciated. When gut transit slows, the bacterial populations in the small and large intestine shift. Species that thrive in slow-transit environments proliferate, while those requiring regular substrate flow decline. This thyroid-driven microbial shift can then impair thyroid hormone metabolism and nutrient absorption, worsening the original hypothyroidism in a feedback loop.
Additionally, levothyroxine, the standard treatment for hypothyroidism, is absorbed primarily in the jejunum and ileum. Conditions that affect the gut lining in these regions, including celiac disease, H. pylori infection, SIBO, and inflammatory bowel disease, can significantly impair levothyroxine absorption (Centanni et al., 2006). This means that gut health directly affects the effectiveness of thyroid medication. A Hashimoto's patient with concurrent untreated gut disease may require higher levothyroxine doses and still achieve suboptimal thyroid levels, not because the dose is wrong but because the gut is not absorbing it properly.
Molecular mimicry and the immune connection
One of the proposed mechanisms linking gut bacteria to Hashimoto's thyroiditis is molecular mimicry. This occurs when bacterial proteins share structural similarity with human thyroid proteins, causing immune cells that were originally trained to attack the bacteria to cross-react with thyroid tissue. Kohling et al. (2017) identified several bacterial peptide sequences with significant homology to thyroid peroxidase (TPO) and thyroglobulin, the two main autoantigens in Hashimoto's thyroiditis.
The molecular mimicry hypothesis is strengthened by the observation that infections and gut perturbations sometimes precede Hashimoto's diagnosis. Some patients report that their thyroid problems began after a gastrointestinal infection, a course of antibiotics, or a period of severe GI distress. While this temporal association does not prove causation, it is consistent with a model where gut barrier disruption exposes the immune system to bacterial antigens that cross-react with thyroid tissue, initiating or amplifying the autoimmune response.
Increased intestinal permeability provides the other half of this mechanism. Even if molecular mimicry potential exists, bacterial antigens need to cross the gut barrier and encounter immune cells to trigger cross-reactive responses. Hashimoto's patients have been shown to have increased intestinal permeability in some studies, and the combination of leaky gut plus mimicry-capable bacteria could lower the threshold for autoimmune activation. This is the same general mechanism proposed for other autoimmune diseases, but the specific bacterial and host protein sequences involved are unique to thyroid autoimmunity.
The IMITHOT trial: can FMT change thyroid autoimmunity?
The IMITHOT trial (Impact of Intestinal Microbiota on Thyroid Hormone Therapy) represents one of the most ambitious direct tests of the thyroid-gut axis hypothesis. Led by Camilla Virili and colleagues in Italy, the trial is testing whether fecal microbiota transplantation from healthy donors into Hashimoto's patients can reduce thyroid autoantibody levels, improve thyroid function, and potentially reduce the dose of levothyroxine needed to maintain normal thyroid levels (Virili et al., 2021).
The trial design involves Hashimoto's patients with documented gut dysbiosis who receive FMT from carefully screened healthy donors. Primary outcomes include changes in anti-TPO and anti-thyroglobulin antibody levels, changes in TSH and free T4 levels, and changes in required levothyroxine dose. Secondary outcomes include changes in gut microbiome composition, intestinal permeability markers, and patient-reported symptoms.
As of early 2026, results from IMITHOT have not been published. If the trial shows that FMT reduces thyroid antibodies or improves thyroid function, it would provide the first direct evidence that correcting gut dysbiosis can alter the course of thyroid autoimmunity in humans. If it shows no effect, it would suggest that gut dysbiosis in Hashimoto's is a downstream consequence of the disease rather than a driver of it, or that FMT alone is insufficient to correct the relevant gut abnormalities. Either result will be informative for the field.
What helps: practical approaches for the thyroid-gut connection
While we await definitive clinical trial data, several approaches are supported by the mechanistic evidence and are generally safe for people with thyroid conditions to consider.
Evidence-informed strategies
- Screen for concurrent gut conditions: If you have Hashimoto's and persistent gut symptoms, testing for celiac disease, H. pylori, and SIBO is worthwhile. Each of these conditions is more common in Hashimoto's patients and can impair levothyroxine absorption.
- Optimize levothyroxine absorption: Take levothyroxine on an empty stomach, 30 to 60 minutes before food, and away from supplements that can interfere with absorption (calcium, iron, and soy within 4 hours). If you have a gut condition affecting absorption, discuss liquid formulations or softgel capsules with your doctor, as these may be absorbed more reliably.
- Support microbial diversity through diet: A diverse, fiber-rich diet supports the bacterial communities involved in thyroid hormone metabolism. Focus on variety of plant sources rather than any single food.
- Ensure adequate selenium and iodine: Both are essential for thyroid function and dependent on gut absorption. Brazil nuts are the richest dietary source of selenium. Iodine sources include seaweed, dairy, and iodized salt. Discuss supplementation with your doctor if you suspect a deficiency.
- Track symptoms systematically: Because the thyroid-gut axis is bidirectional, changes in thyroid medication, diet, or gut health can affect both systems. Using a tool like GLP1Gut to log digestive symptoms alongside thyroid-related symptoms like fatigue, temperature sensitivity, and brain fog can help identify patterns that inform your management.
- Address constipation proactively: Hypothyroidism-related constipation alters the gut microbiome and may worsen the thyroid-gut feedback loop. Adequate fiber, hydration, and physical activity are first-line approaches, with osmotic laxatives as a backup if needed.
It is important to note that no probiotic supplement has been proven to improve thyroid function in a well-designed human trial. Some small studies have reported encouraging results, but they are too preliminary to base clinical decisions on. Products marketed for 'thyroid support' through the gut are making claims the evidence cannot currently justify.
**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider about your specific health concerns.
Can gut problems cause thyroid disease?
The evidence supports a contributing role rather than a sole cause. Gut dysbiosis, increased intestinal permeability, and molecular mimicry between bacterial and thyroid proteins are plausible mechanisms through which gut problems could initiate or amplify thyroid autoimmunity. However, thyroid disease also has strong genetic components, and gut dysbiosis alone is unlikely to cause Hashimoto's in someone without genetic susceptibility. The relationship is bidirectional, with thyroid dysfunction also impairing gut health.
Why does my levothyroxine not seem to work even at higher doses?
Several gut conditions can impair levothyroxine absorption, including celiac disease, H. pylori infection, SIBO, lactose intolerance (for tablets containing lactose), and inflammatory bowel disease. If your TSH remains elevated despite increasing doses, ask your doctor about testing for these conditions. Switching to a liquid or softgel formulation may also improve absorption in patients with gut-related malabsorption.
What is the IMITHOT trial?
IMITHOT (Impact of Intestinal Microbiota on Thyroid Hormone Therapy) is a clinical trial testing whether fecal microbiota transplantation from healthy donors can reduce thyroid autoantibodies, improve thyroid function, and reduce levothyroxine requirements in Hashimoto's patients. It is one of the first direct tests of whether correcting gut dysbiosis can change thyroid autoimmune outcomes. Results have not been published as of early 2026.
Do gut bacteria really help convert T4 to T3?
Yes. Approximately 20% of T4 to T3 conversion occurs outside the liver and kidneys, with a significant portion occurring in the gut. Gut bacteria produce deiodinase and sulfatase enzymes that participate in thyroid hormone activation and recycling. When gut dysbiosis reduces these bacterial populations, peripheral T3 availability may decrease. However, the exact quantitative contribution of gut-based conversion relative to hepatic conversion varies between individuals and is not precisely established.
Should Hashimoto's patients take probiotics?
There is not enough evidence to make a specific recommendation. Some small studies have reported modest improvements in thyroid markers with certain probiotic strains, but no large trial has confirmed these findings. Maintaining gut microbial diversity through diet, addressing concurrent gut conditions, and optimizing levothyroxine absorption are better-supported first steps. If you choose to try probiotics, discuss it with your doctor and monitor your thyroid levels, as changes in gut health could potentially affect levothyroxine absorption.